Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089903 | 1.00 | NR1H4 (0.44) | NR1H4MAOBMAOAALDH1A1LTB4R | |
| SCHEMBL1131974 | 0.84 | NR1H4 (0.62) | NR1H4MAOBALDH1A1LTB4RLTB4R2 | |
| SCHEMBL1131978 | 0.84 | NR1H4 (0.62) | NR1H4MAOBALDH1A1LTB4RLTB4R2 | |
| SCHEMBL934271 | 0.83 | MAOB (0.54) | MAOBMAOAALDH1A1PARP10RAB9A | |
| SCHEMBL934270 | 0.83 | MAOB (0.54) | MAOBMAOAALDH1A1PARP10RAB9A | |
| SCHEMBL2088021 | 0.81 | ALDH1A1 (0.59) | MAOBMAOAALDH1A1PARP15PARP14 | |
| SCHEMBL1064742 | 0.80 | PLA2G4B (0.46) | MAOBMAOAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1064741 | 0.80 | PLA2G4B (0.46) | MAOBMAOAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL12860193 | 0.80 | TP53 (0.52) | TP53MAPTKMT2A | |
| SCHEMBL934159 | 0.80 | SMN1; SMN2 (0.59) | NR1H4MAOBALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | claimed |
| US-6946491-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR1H4 127/4885MAOB 589/4885MAOA 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.